FDA approves Vascepa, a fish-oil-derived medication that could help prevent heart attacks, strokes and death in people who are at high cardiovascular risk.
FDA approves omega-3 fatty drug to reduce heart disease, stroke and death
Vascepa, which is the only product made by pharmaceutical company Amarin, could be prescribed to millions of patients. The Centers for Disease Control and Prevention report that nearly 95 million Americans have high cholesterol. High cholesterol is a condition in which increased levels of fats, like LDL-C and triglycerides, build up in the blood and raise the risk of heart disease and stroke.Heart disease remains the No.
This undated photo provided by Amarin in November 2018 shows a capsule of the purified, prescription fish oil Vascepa. On Friday, Dec. 13, 2019, U.S. regulators approved expanded use of the medication for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills.Over-the-counter oils may contain a combination of eicosapentaenoic acid and docosahexaenoic acid .
"I expect Vascepa to do well," Pink said."I have been up against some very serious heart issues, and I have lived with the fact that I am a high-risk patient. Seeing my triglyceride levels come down will be reassuring."
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA approves fish-oil drug for cutting cardiac risksIn patient testing, the drug reduced risks of potentially deadly complications including heart attacks and strokes about 25 percent.
Read more »
FDA approves fish-oil drug for cutting cardiac risksIn patient testing, the drug reduced risks of potentially deadly complications including heart attacks and strokes about 25 percent.
Read more »
Oil prices fall but hold near three-month high on trade deal agreementOil prices fell but remained near three-month highs on Monday after the United S...
Read more »
Vanilla Chia Seed PuddingGet your omega-3s right here.
Read more »
Top technology analyst Sacconaghi believes the sector is quite risky heading into 2020'Given elevated valuations and elevated expectations for high priced stocks, we believe risk remains high in tech,' the analyst said.
Read more »